Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors inside the central nervous method, conolidine modulates alternate molecular targets. A Science Advancements review located that conolidine interacts Together with the atypical chemokine receptor ACKR3